A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Studien-Informationen

Ein-/Ausschlusskriterien

Studien-Rationale

Geprüfte Regime

• Docetaxel:
  Docetaxel will be administered as per local prescribing information.
• Paclitaxel:
  Paclitaxel will be administered as per local prescribing information.
• Pertuzumab (Perjeta):
  Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
• Trastuzumab (Herceptin):
  Trastuzumab will be administered as per local prescribing information.
• Trastuzumab Emtansine (Kadcyla; T-DM1):
  Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
• Atezolizumab (Tecentriq):
  Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)

Quelle: ClinicalTrials.gov